Bolt Biotherapeutics, Inc. (BOLT) vs Lexaria Bioscience Corp. (LEXX)

Bolt Biotherapeutics, Inc. and Lexaria Bioscience Corp. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Lexaria Bioscience Corp. are of similar size ($7.1M and $6.9M). Bolt Biotherapeutics, Inc. grew revenue faster over the last twelve months: 12.8% against 9.08%. Lexaria Bioscience Corp. has the higher net margin (0.00% vs −611.5%) and the lower return on invested capital (−662.6% vs −143.8%). Across the 17 metrics below, Bolt Biotherapeutics, Inc. leads on 9 and Lexaria Bioscience Corp. on 8.

Valuation

Metric BOLT LEXX Biotechnology median
P/E n/m n/m 7.88
P/S 1.32 10.01 11.47
P/B 0.49 1.25 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.48 3.66 10.73
Earnings yield (447.96%) (155.41%) (28.84%)
Free cash flow yield (496.60%) (138.70%) (23.03%)

Profitability

Metric BOLT LEXX Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (654.53%) 0.00% 0.00%
Net margin (611.47%) 0.00% 0.00%
Free cash flow margin (655.72%) 0.00% 0.00%
Return on equity (111.65%) (162.60%) (57.72%)
Return on assets (49.62%) (134.20%) (49.22%)
Return on invested capital (143.75%) (662.56%) 0.00%

Growth

Metric BOLT LEXX Biotechnology median
Revenue growth (TTM) 12.79% 9.08% 5.64%
EPS growth (last fiscal year) 45.91% (40.43%) —
Revenue growth, 5-year CAGR 101.61% 17.53% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BOLT LEXX Biotechnology median
Debt to equity 1.47 0.00 0.00
Current ratio 2.61 10.60 4.73
Net debt to EBITDA 0.21 0.17 0.96

Dividend

Metric BOLT LEXX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BOLT LEXX Biotechnology median
Market cap 6.92m 7.10m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack